ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO634

Safety and Single Ascending Dose Pharmacokinetic Study of DUR-928 in Patients with CKD versus Matched Control Subjects

Session Information

  • Pharmacology
    October 27, 2018 | Location: Exhibit Hall, San Diego Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

  • 1700 Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)


  • Shah, Jaymin C., DURECT Corporation, Cupertino, California, United States
  • Ellis, David J., DURECT Corporation, Cupertino, California, United States
  • Miksztal, Andrew R., DURECT Corporation, Cupertino, California, United States
  • Lin, Wei Qi, DURECT Corporation, Cupertino, California, United States

DUR-928 ((5-cholesten-3β,25-diol 3-sulfate (25HC3S)) is an endogenous intracellular sulfated oxysterol that has been shown to regulate lipid metabolism, inflammatory response, and cell survival. This first-in-class investigational product is being developed for the treatment of various liver and kidney diseases. Animal ADME studies have shown that ≈ 17% of DUR-928 is eliminated through the urine. This study was to evaluate the impact of renal impairment in chronic kidney disease (CKD), on the safety and pharmacokinetics (PK) of DUR-928.


The study was a Phase 1b, open label, single ascending dose study to evaluate the safety and PK of IM injected DUR-928 in patients with moderate and severe kidney function impairment (Stage 3 and Stage 4 CKD) and matched control subjects (MCS), matched by age, BMI, and gender, with normal kidney function. The two doses of DUR-928 in the study were 30 mg and 120 mg. Biomarkers were also examined. All study subjects were followed through 7 days post dosing.


Eleven CKD patients (Stage 3 (N=8), Stage 4 (N=3)) and six MCS completed the study. A total of 13 TEAEs were reported by 8 participants, mostly mild and none were severe. A clinically non-significant decrease (≈ 10%) in exposure was observed in CKD patients as compared to MCS at both dose levels of DUR-928. The AUC values for 30 and 120 mg doses in CKD patients were 1061 and 4304 ng*hr/mL vs. 1138 and 4766 ng*hr/mL in MCS. Similarly, the Cmax values for 30 and 120 mg doses in CKD patients were 281 and 890 ng/mL vs. 345 and 997 ng/mL in MCS. The plasma half-life (T½) was in the range of 1.5 to 2 hours. Participants with elevated levels of CK-18 (markers of cell death) or bilirubin at baseline showed considerable reduction of these markers at 12 or 24 - 48 hours after a single IM injection of DUR-928.


Single IM doses of DUR-928 in CKD patients were found to be well tolerated. Kidney function impairment did not impact the PK of DUR-928. These data support further evaluation of DUR-928 in patients with kidney disease.